LGT Fund Management Co Ltd. Has $372,000 Holdings in Bristol Myers Squibb Company $BMY

LGT Fund Management Co Ltd. trimmed its position in shares of Bristol Myers Squibb Company (NYSE:BMY) by 87.6% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 7,844 shares of the biopharmaceutical company’s stock after selling 55,260 shares during the period. LGT Fund Management Co Ltd.’s holdings in Bristol Myers Squibb were worth $372,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently modified their holdings of the company. Vanguard Group Inc. lifted its stake in Bristol Myers Squibb by 0.5% in the 3rd quarter. Vanguard Group Inc. now owns 195,984,009 shares of the biopharmaceutical company’s stock valued at $8,838,879,000 after purchasing an additional 1,058,803 shares during the last quarter. Charles Schwab Investment Management Inc. increased its holdings in shares of Bristol Myers Squibb by 16.8% during the 2nd quarter. Charles Schwab Investment Management Inc. now owns 70,802,680 shares of the biopharmaceutical company’s stock worth $3,277,456,000 after acquiring an additional 10,195,775 shares during the last quarter. Geode Capital Management LLC raised its stake in Bristol Myers Squibb by 1.6% in the 2nd quarter. Geode Capital Management LLC now owns 46,176,690 shares of the biopharmaceutical company’s stock valued at $2,132,976,000 after acquiring an additional 723,459 shares during the period. Norges Bank bought a new position in Bristol Myers Squibb during the second quarter worth $1,554,154,000. Finally, Ameriprise Financial Inc. lifted its stake in shares of Bristol Myers Squibb by 1.3% during the 2nd quarter. Ameriprise Financial Inc. now owns 32,579,618 shares of the biopharmaceutical company’s stock worth $1,508,099,000 after buying an additional 432,158 shares during the last quarter. Institutional investors own 76.41% of the company’s stock.

Bristol Myers Squibb Price Performance

BMY stock opened at $60.59 on Tuesday. The company’s 50-day moving average price is $57.79 and its two-hundred day moving average price is $51.12. The firm has a market cap of $123.38 billion, a P/E ratio of 17.56, a P/E/G ratio of 0.17 and a beta of 0.26. The company has a quick ratio of 1.14, a current ratio of 1.26 and a debt-to-equity ratio of 2.32. Bristol Myers Squibb Company has a 12 month low of $42.52 and a 12 month high of $63.33.

Bristol Myers Squibb (NYSE:BMY) last posted its quarterly earnings results on Thursday, February 5th. The biopharmaceutical company reported $1.26 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.65 by ($0.39). The firm had revenue of $12.50 billion for the quarter, compared to analyst estimates of $12.24 billion. Bristol Myers Squibb had a return on equity of 69.65% and a net margin of 14.64%.The business’s revenue was up 1.3% on a year-over-year basis. During the same quarter in the prior year, the business posted $1.67 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. On average, analysts anticipate that Bristol Myers Squibb Company will post 6.74 earnings per share for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, May 1st. Stockholders of record on Thursday, April 2nd will be paid a $0.63 dividend. The ex-dividend date is Thursday, April 2nd. This represents a $2.52 annualized dividend and a dividend yield of 4.2%. Bristol Myers Squibb’s dividend payout ratio (DPR) is presently 73.04%.

Bristol Myers Squibb News Roundup

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: FDA approves an expanded label for Sotyktu (BMY’s TYK2 inhibitor) for psoriatic arthritis after strong POETYK data — this broadens the drug’s commercial opportunity and supports revenue growth for the immunology portfolio. BMY Wins FDA Nod to Expand Sotyktu Label for Psoriatic Arthritis
• Positive Sentiment: Positive Phase 3 SUCCESSOR-2 results for oral mezigdomide in relapsed/refractory multiple myeloma — a successful registrational trial materially improves approval and commercialization prospects for this CELMoD asset. Bristol Myers Squibb Announces Positive Phase 3 Results from the SUCCESSOR-2 Study
• Positive Sentiment: Late‑stage cancer trial met its primary endpoint and another trial reported improved survival in a late‑stage blood cancer study — these clinical successes reduce execution risk and increase the potential for new oncology approvals and revenue. Bristol’s cancer treatment meets main goal in late-stage trial Bristol’s drug enhances survival rates in late-stage blood cancer trial
• Neutral Sentiment: Market commentary and investor interest pieces (Zacks/Yahoo) note heightened attention in BMY and review valuation/earnings outlooks — these can drive trading volume but are not new company catalysts by themselves. Is Trending Stock Bristol Myers Squibb Company (BMY) a Buy Now? Is Trending Stock Bristol Myers Squibb Company (BMY) a Buy Now?
• Neutral Sentiment: Analysts maintain a consensus “Hold” on BMY — indicates mixed views on valuation vs. growth prospects despite recent clinical wins. Bristol Myers Squibb Company Given Consensus Rating of “Hold”
• Neutral Sentiment: Longer-form investor coverage (Fool) credits BMY’s growth portfolio for offsetting legacy declines and highlights development progress — useful context for medium-term thesis but not an immediate catalyst. Why Bristol Myers Squibb Stock Crushed it in February
• Neutral Sentiment: Broader industry report on anticoagulants shows market growth but is not specific to BMY’s pipeline/products and is therefore a background industry tailwind rather than a direct company catalyst. Anticoagulants Market Competitive Analysis Report 2025
• Neutral Sentiment: Third‑party portfolio review (Virtus Large Cap Growth SMA) mentions overall fund performance; BMY was not a highlighted driver and the item is unlikely to move BMY stock materially. Virtus Large Cap Growth SMA Q4 2025 Portfolio Review

Analyst Ratings Changes

BMY has been the subject of several research reports. Barclays started coverage on shares of Bristol Myers Squibb in a research report on Thursday, February 19th. They set an “overweight” rating and a $75.00 price objective for the company. Guggenheim reaffirmed a “buy” rating and issued a $72.00 target price (up from $62.00) on shares of Bristol Myers Squibb in a research report on Friday, February 6th. Truist Financial set a $65.00 target price on Bristol Myers Squibb in a research note on Wednesday, December 3rd. Bank of America raised Bristol Myers Squibb from a “neutral” rating to a “buy” rating and lifted their price target for the stock from $52.00 to $61.00 in a report on Monday, December 15th. Finally, Morgan Stanley reaffirmed an “underweight” rating and issued a $40.00 price objective on shares of Bristol Myers Squibb in a report on Friday, February 6th. Nine research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Bristol Myers Squibb has a consensus rating of “Hold” and an average price target of $61.00.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.